---
title: iotaSciences and Quantum Design China enter into distribution agreement
description: iotaSciences and Quantum Design China have today announced an exclusive distribution agreement for iotaSciences proprietary single cell handling platforms in China.
image: https://news.lifesciencenewswire.com/hubfs/23.jpg
---

[![Life Science Newswire 2](https://news.lifesciencenewswire.com/hs-fs/hubfs/Life%20Science%20Newswire%202.png?width=203&height=60&name=Life%20Science%20Newswire%202.png "Life Science Newswire 2")](https://lifesciencenewswire.com/)

- [Newsroom](https://news.lifesciencenewswire.com/newsroom)
- [Back to the main site](https://lifesciencenewswire.com/)

![LSNewswire-main-header-banner-v2-1](https://news.lifesciencenewswire.com/hubfs/LSNewswire-main-header-banner-v2-1.jpg "LSNewswire-main-header-banner-v2-1")

# Newsroom

#### Categories ![Arrow](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/sidebar.svg "Arrow")

#### Subscribe![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/subscribe-rss-button.svg)

![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/close-button.svg)

### Choose a Category

- [Agriculture (1)](https://news.lifesciencenewswire.com/newsroom/tag/agriculture)
- [Analytical Chemistry (42)](https://news.lifesciencenewswire.com/newsroom/tag/analytical-chemistry)
- [Biomanufacturing (34)](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing)
- [biopharma (20)](https://news.lifesciencenewswire.com/newsroom/tag/biopharma)
- [Bioprocessing (15)](https://news.lifesciencenewswire.com/newsroom/tag/bioprocessing)
- [Biotechnology (244)](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology)
- [Cell Culture (9)](https://news.lifesciencenewswire.com/newsroom/tag/cell-culture)
- [Clinical Diagnostics (36)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-diagnostics)
- [clinical research (6)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research)
- [Clinical Research & Trials (108)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials)
- [Computing & Technology (62)](https://news.lifesciencenewswire.com/newsroom/tag/computing-it)
- [Corporate, Finance & Investor (283)](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor)
- [COVID-19 (86)](https://news.lifesciencenewswire.com/newsroom/tag/covid-19)
- [Diagnostics & Hospital Laboratory (35)](https://news.lifesciencenewswire.com/newsroom/tag/diagnostics-hospital-laboratory)
- [Drug Discovery & Development (147)](https://news.lifesciencenewswire.com/newsroom/tag/drug-discovery-development)
- [Energy & Environment (15)](https://news.lifesciencenewswire.com/newsroom/tag/energy-environment)
- [excipients (1)](https://news.lifesciencenewswire.com/newsroom/tag/excipients)
- [Food & Beverage (8)](https://news.lifesciencenewswire.com/newsroom/tag/food-beverage)
- [General Chemistry (7)](https://news.lifesciencenewswire.com/newsroom/tag/general-chemistry)
- [General Laboratory (55)](https://news.lifesciencenewswire.com/newsroom/tag/general-laboratory)
- [General Science (5)](https://news.lifesciencenewswire.com/newsroom/tag/general-science)
- [Healthcare (132)](https://news.lifesciencenewswire.com/newsroom/tag/healthcare)
- [Hospital Management (6)](https://news.lifesciencenewswire.com/newsroom/tag/hospital-management)
- [Life Science (26)](https://news.lifesciencenewswire.com/newsroom/tag/life-science)
- [Manufacturing (2)](https://news.lifesciencenewswire.com/newsroom/tag/manufacturing)
- [Materials Science (2)](https://news.lifesciencenewswire.com/newsroom/tag/materials-science)
- [Medical Devices & Technology (25)](https://news.lifesciencenewswire.com/newsroom/tag/medical-devices-technology)
- [Microbiology & Infection Control (18)](https://news.lifesciencenewswire.com/newsroom/tag/microbiology-infection-control)
- [Microscopy & Imaging (47)](https://news.lifesciencenewswire.com/newsroom/tag/microscopy-imaging)
- [Nanotech (2)](https://news.lifesciencenewswire.com/newsroom/tag/nanotech)
- [Omics & Genetics (86)](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics)
- [Pathology (5)](https://news.lifesciencenewswire.com/newsroom/tag/pathology)
- [Pharma (114)](https://news.lifesciencenewswire.com/newsroom/tag/pharma)
- [Pharmacy (4)](https://news.lifesciencenewswire.com/newsroom/tag/pharmacy)
- [Research (47)](https://news.lifesciencenewswire.com/newsroom/tag/research)
- [Veterinary (5)](https://news.lifesciencenewswire.com/newsroom/tag/veterinary)
- [Water (8)](https://news.lifesciencenewswire.com/newsroom/tag/water)

See all

### Subscribe to Email Updates

- ##### SHARE
- <https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fnews.lifesciencenewswire.com%2Fnewsroom%2Fiotasciences-and-quantum-design-china-enter-into-distribution-agreement>
- <https://www.twitter.com/share?url=https%3A%2F%2Fnews.lifesciencenewswire.com%2Fnewsroom%2Fiotasciences-and-quantum-design-china-enter-into-distribution-agreement>
- <http://www.linkedin.com/shareArticle?mini=true&url=https://news.lifesciencenewswire.com/newsroom/iotasciences-and-quantum-design-china-enter-into-distribution-agreement>

# [iotaSciences and Quantum Design China enter into distribution agreement](https://news.lifesciencenewswire.com/newsroom/iotasciences-and-quantum-design-china-enter-into-distribution-agreement)

 September 6, 2023

Exclusive partnership will provide access for customers in China to iotaSciences proprietary single cell handling platforms based on its proprietary fluid-shaping technology

iotaSciences, the Oxford-based leader in the rapidly growing field of single-cell handling solutions, and Quantum Design China, a subsidiary of Quantum Design International, announced today an exclusive distribution agreement for iotaSciences proprietary single cell handling platforms in China.

"We are pleased to now offer customers in China access to iotaSciences platforms, which allows scientists to access highly user-friendly, reliable, and powerful single cell handling technologies and solutions with unique capabilities that greatly simplify and facilitate breakthrough advances in cell biology and gene therapy” said Lambert Cao, General Manager of Quantum Design China. "We look forward to working closely with the iotaSciences team to introduce this unique technology to the rapidly expanding field of single cell biological applications."

Ed Walsh, iotaSciences Founding Director & Chief Innovation Officer commented: “We are highly excited about this next step with Quantum Design China to see our innovative technology being deployed across the Chinese scientific community. Our proprietary fluid-shaping technology has translated very well into tangible user benefits for single-cell handling workflows as required in many frontiers research fields including CRISPR, iPSCs and gene therapy workflows”.

Dr. Michael Lutz, iotaSciences recently appointed CEO added: “This partnership with Quantum Design China is another key milestone for the company´s future development path after the recent acceleration of its commercial activities leading to a doubling of its installed base in the last year. Quantum Design China is the ideal partner for us to team up with given its in-depth knowledge of optimally serving academic and industrial scientists in the life science market in China.”

About iotaSciences ([https://iotasciences.com/)](https://iotasciences.com/\))

iotaSciences is a spin-out from the University of Oxford (UK), founded in 2016 by scientists from the Department of Engineering Science and the Sir William Dunn School of Pathology. Since its inception, iotaSciences has been committed to offering researchers highly user-friendly, reliable, and powerful single cell handling technologies and solutions with unique capabilities that greatly simplify and facilitate breakthrough advances in cell biology and gene therapy.

About Quantum Design China ([https://www.qd-china.com/en)](https://www.qd-china.com/en\))

Established in 2004, Quantum Design (Beijing) Co., Ltd., a subsidiary of Quantum Design International, distributes a wide range of scientific and industrial technologies in China. The company's team of highly trained sales and technical service professionals offers distribution partners sales and after-sales technical support, providing the highest level of product knowledge and expertise to academic and industrial scientists in life science and materials research markets.

 Categories: [Biotechnology](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology), [Corporate, Finance & Investor](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor)

##### Browse more news

## Recent releases

<https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai>

#### [Enhanced Compliance Inc. (ECI) Appoints Taranjit S. Samra as Head of Medical Device Software Enginee...](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai)

 July 6, 2026

Strengthens ECI’s AI & Digital Transformation capabilities to help clients develop the next generation of software-enabled medical technologies En...

##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai)

<https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale>

#### [Alithea Genomics Launches Early Access Program for MERCURIUS™ 1536 DRUG-seq, Bringing Transcriptomic...](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale)

 June 16, 2026

New ultra-high-throughput kit enables discovery teams to generate transcriptome-wide compound-response data directly from 1536-well plates Alithea Gen...

##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale)

<https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer>

#### [Arscience Biotherapeutics Appoints Gustavo Mahler as Chief Executive Officer](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer)

 June 16, 2026

Seasoned Biopharmaceutical Leader and Board Director Steps Up to Lead the Company’s Next Phase of Growth in Customized Interleukin Therapies ARScience...

##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer)

![LS-Newswire-reverse](https://news.lifesciencenewswire.com/hs-fs/hubfs/raw_assets/public/LifeScienceNewswire_June2020/images/LS-Newswire-reverse.png?width=150&name=LS-Newswire-reverse.png "LS-Newswire-reverse")

Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225 

#### Useful information

- [Cookie and privacy policy](https://lifesciencenewswire.com/cookie-privacy-policy/)
- [Website terms and conditions](https://lifesciencenewswire.com/terms-and-conditions)
- [Promotion terms and conditions](https://lifesciencenewswire.com/promotion_terms/)